Methylone

Methylone (3,4-methylenedioxymethcathinone), also known as bk-MDMA, MDMC, or M1, is a synthetic cathinone stimulant. Chemically it is the beta-keto analogue of MDMA — essentially MDMA with one added oxygen atom — which is why its effects resemble ecstasy. First synthesized in the 1990s and explored for possible therapeutic use, it emerged as a recreational "new psychoactive substance" around 2004 and was sold as a "legal" MDMA substitute and as a component of "bath salts." It usually appears as a powder, crystals, or in capsules and is typically swallowed. Its recreational popularity peaked around 2011-2015 but it remains one of the more common synthetic cathinones.

Methylone acts on the brain's monoamine systems much like MDMA, its close structural relative. It works mainly as a releaser of serotonin, dopamine, and norepinephrine, with a dopamine-to-serotonin balance (a transporter ratio of about 1.8) reasonably close to MDMA's — and far more serotonin-weighted than pure stimulants like methamphetamine. This releaser mechanism groups it with mephedrone rather than with MDPV, which is a reuptake blocker. The relatively strong serotonin component is what gives methylone its MDMA-like empathogenic quality — feelings of closeness and emotional openness — alongside general stimulation.

In controlled human studies and user reports, methylone produces the prototypical MDMA-like combination of stimulation and empathogenic effects — euphoria, increased energy, sociability, emotional warmth, and altered perception — but generally at lower intensity than an equivalent experience with MDMA. Onset is relatively quick and the effects are shorter-lived than MDMA's, which encourages redosing. Common unwanted effects mirror other stimulant-empathogens: jaw tension, raised heart rate and blood pressure, sweating, and difficulty sleeping.

As a stimulant-empathogen, methylone carries the cardiovascular and overheating risks common to this drug class: elevated heart rate and blood pressure, hyperthermia (especially in warm, crowded settings with physical activity), agitation, and — as with MDMA — a risk of dangerous serotonin excess, particularly if combined with other serotonergic drugs such as MDMA, some antidepressants, or MAO inhibitors. Its shorter duration promotes redosing, which increases total exposure and strain. Contents of products sold as methylone vary and may be another cathinone entirely. Repeated use can lead to low mood, anxiety, and dependence.